MedDataX Logo

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

NCT ID: NCT00176956

Last Updated: 2013-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The skin disease found in pediatric heart transplant patients represents an atopic dermatitis-like rash that is refractory to systemic immunomodulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703

Atopic Dermatitis Eczema
ACTIVE_NOT_RECRUITING

Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

NCT05819463

Atopic Dermatitis
RECRUITING

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359

Dermatitis Atopic
ACTIVE_NOT_RECRUITING

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

NCT01232985

Atopic Dermatitis Pruritus
COMPLETED PHASE2

Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up

NCT00795496

Atopic Dermatitis
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We want to determine whether pediatric heart transplant patients with an atopic dermatitis-like rash report a personal and/or family history of atopy (asthma, allergies and atopic dermatitis). In addition comparisons will be made between the presence of atopy between patients with and without the skin rash. Comparisons will be made of systemic immunosuppressive therapies between patients with and without the atopic dermatitis-like rash. Determination will be made as to whether histologic characterization of a skin biopsy specimen is consistent with AD. Thorough evaluations will be made of patients in the clinic with this rash and the presence of bacterial superinfection will be ruled out.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin Biopsy

Skin biopsy.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Skin biopsy.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have had a heart transplant.
* Patients must be less than 16 years of age.

Exclusion Criteria

* Patients who have not had a heart transplant.
* Patients who are greater than 16 years of age.
Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hordinsky, Maria K., MD

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Hordinsky, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0110M09983

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis
NCT02289989 TERMINATED NA
Treatment of Nighttime Pruritus in Atopic Dermatitis
NCT03688464 WITHDRAWN EARLY_PHASE1
Moisturizer to Prevent Atopic Dermatitis
NCT03808532 WITHDRAWN PHASE2
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis
NCT01234909 TERMINATED
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392 TERMINATED PHASE4
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
NCT05200403 TERMINATED PHASE4
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
NCT04921969 COMPLETED PHASE3
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
NCT03089476 WITHDRAWN NA
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258 RECRUITING PHASE4
Systemic Therapies for Pediatric Atopic Dermatitis
NCT01447381 UNKNOWN
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
NCT03059693 COMPLETED PHASE1/PHASE2
Comprehending Atopic Risk Elements
NCT04325451 UNKNOWN
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
NCT00616096 COMPLETED NA
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
NCT06309355 COMPLETED PHASE2
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
NCT05056779 WITHDRAWN PHASE3
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
NCT06055374 WITHDRAWN PHASE1
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
NCT03257644 COMPLETED PHASE1
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
NCT05034822 COMPLETED PHASE1
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333 COMPLETED PHASE1/PHASE2
Atopic Dermatitis (AD) and Food Allergy
NCT03168113 COMPLETED
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
NCT06983561 RECRUITING
Targeted Microbiome Transplant in Atopic Dermatitis
NCT03151148 COMPLETED PHASE1/PHASE2
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
NCT03568071 TERMINATED PHASE2
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03864627 TERMINATED PHASE2
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
NCT03389893 TERMINATED PHASE4